Exploring the Precision Oncology Market: 5 Promising Stocks in a $317 Billion Arena The precision oncology market is expected to grow significantly, reaching $317.5 billion by 2035. Discover 5 key stocks poised for growth in this transformative space.

Exploring the Precision Oncology Market: 5 Promising Stocks in a $317 Billion Arena #USA #Vancouver #Oncolytics_Biotech #Veracyte #Exact_Sciences

Helix and Veracyte Team Up for Enhanced Genomic Insights in Prostate Cancer Treatment Helix has partnered with Veracyte to improve access to genetic testing in prostate cancer, enhancing patient care with actionable insights.

Helix and Veracyte Team Up for Enhanced Genomic Insights in Prostate Cancer Treatment #USA #San_Mateo #Helix #Veracyte #Genomic_Insights

Veracyte stock soars after S&P SmallCap 600 addition announcement Investing.com -- Veracyte Inc (NASDAQ:VCYT) stock surged 7.6% following news that the company will be added to the S&P SmallCap 600 index effective prior to market open on Tuesday, July 29, 2025. The diagnostic test maker will replace Triumph Group Inc (NYSE:TGI) in the small-cap benchmark as Triumph is being acquired by Warburg Pincus LLC and Berkshire Partners LLC. The acquisition is expected to close soon, pending final closing conditions. Index additions typically drive stock price increases as funds tracking the benchmark need to purchase shares of the newly added company. Veracyte’s inclusion in the S&P SmallCap 600 represents a significant milestone for the health care company, potentially increasing its visibility among investors. The index change will take effect before markets open on July 29, with Veracyte joining the Health Care sector of the index while Triumph Group exits from the Industrials sector. Veracyte specializes in genomic diagnostics, developing and commercializing tests that help physicians improve diagnostic accuracy and optimize patient care. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Veracyte #StockMarket #Investing #SmallCap #NASDAQ

Veracyte to Join the S&P SmallCap 600 Index in Landmark Move Veracyte Inc. is set to replace Triumph Group in the S&P SmallCap 600, effective July 29, marking a significant milestone for the company.

Veracyte to Join the S&P SmallCap 600 Index in Landmark Move #USA #New_York #TRIUMPH_Group #SP_SmallCap_600 #Veracyte

🔬 Veracyte menace d'arrêter sa R&D à Marseille. Je demande une table ronde urgente pour préserver les emplois et les investissements, cruciaux pour des projets comme le Marseille Immunology Cluster. #Recherche #Marseille #Veracyte